FT商学院

UK biotech takes on personalised cancer therapy side effects

Autolus hopes its less gruelling Car-T treatment for a type of leukaemia will allow it to compete with bigger rivals
Autolus will process, manufacture and ship to the US a new Car-T cell therapy to treat the blood cancer acute lymphoblastic leukaemia

Beyond the discount retailers and chain coffee shops in Stevenage High Street stands a facility manufacturing the latest generation of an innovative, personalised cancer treatment.

From the heart of the English commuter town, UK biotech Autolus will process, manufacture and ship to the US a new Car-T cell therapy to treat the blood cancer acute lymphoblastic leukaemia (ALL), after it received the green light from the US Food and Drug Administration in November.

您已阅读10%(597字),剩余90%(5526字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×